Norinchukin Bank The Acquires 818 Shares of Revvity Inc. $RVTY

Norinchukin Bank The lifted its holdings in Revvity Inc. (NYSE:RVTY) by 15.0% during the first quarter, HoldingsChannel.com reports. The firm owned 6,266 shares of the company’s stock after purchasing an additional 818 shares during the period. Norinchukin Bank The’s holdings in Revvity were worth $663,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its position in Revvity by 25.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock worth $1,011,863,000 after acquiring an additional 1,932,314 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Revvity by 8.5% during the first quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock worth $2,382,163,000 after acquiring an additional 1,754,403 shares in the last quarter. EdgePoint Investment Group Inc. raised its position in Revvity by 51.1% during the fourth quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company’s stock worth $452,939,000 after acquiring an additional 1,372,456 shares in the last quarter. GAMMA Investing LLC raised its position in Revvity by 15,023.0% during the first quarter. GAMMA Investing LLC now owns 287,035 shares of the company’s stock worth $30,368,000 after acquiring an additional 285,137 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Revvity during the first quarter worth $28,060,000. Institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

NYSE:RVTY opened at $94.0390 on Monday. Revvity Inc. has a one year low of $85.12 and a one year high of $129.50. The company has a market cap of $10.92 billion, a P/E ratio of 39.85, a P/E/G ratio of 2.53 and a beta of 0.91. The firm’s fifty day moving average price is $94.57 and its two-hundred day moving average price is $98.75. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. During the same period in the previous year, the company earned $1.22 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Equities analysts expect that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio is 11.86%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. UBS Group raised shares of Revvity from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Raymond James Financial reaffirmed an “outperform” rating and set a $115.00 price target (down from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. The Goldman Sachs Group dropped their price target on shares of Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Bank of America decreased their price objective on shares of Revvity from $116.00 to $110.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Finally, Robert W. Baird decreased their price objective on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, April 29th. Ten research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.